Rolling Out4h
Failed ALS trials reveal major medical breakthrough
Innovative platform trial revolutionizes ALS research by testing multiple treatments simultaneously, offering new hope ...
Medscape2d
ALS Trials Fail to Meet Key Endpoints…But It’s Still a Win and Here’s Why
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
emjreviews.com3d
HEALEY Trial: Pridopidine Fails to Slow ALS Progression
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Platform trials streamline ALS therapy evaluation by rapidly ruling out ineffective drugs
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
manilatimes1d
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...
The Bakersfield Californian1d
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL ...
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS ...
Daily6d
Verdiperstat use may not impact progression of amyotrophic lateral sclerosis: JAMA
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
ALS News Today5d
Results published for first 4 drugs in HEALEY trial; 2 to be tested further
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
pharmaphorum4d
Denali slides after ALS drug flunks clinical test
Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.